Interaction studies of an anticancer alkaloid, (+)-(13aS)- deoxytylophorinine, with calf thymus dna and four repeated double-helical DNAs

Chemotherapy

Volumn 57, Issue 4, 2011, Pages 310-320

  Liu, Zhenjia ^a   Lv, Haining ^a   Li, Hongyan ^a   Zhang, Yi ^a   Zhang, Haijing ^a   Su, Fuqin ^a   Xu, Song ^a   Li, Yong ^a   Si, Yikang ^a   Yu, Shishan ^a   Chen, Xiaoguang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

(+) (13aS) deoxytylophorinine; Anticancer alkaloid; Chemotherapy; DNA intercalation; DNA ligand interaction; Phenanthroindolizidine

Indexed keywords

ANTINEOPLASTIC ALKALOID; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DEOXYTYLOPHORININE; DOUBLE STRANDED DNA; PHENANTHROINDOLIZIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CIRCULAR DICHROISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SEQUENCE; DRUG DNA INTERACTION; DRUG EFFECT; FLUORESCENCE SPECTROSCOPY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MEDICINAL PLANT; MOUSE; NONHUMAN; PLANT ROOT; PRIORITY JOURNAL; SPECTROSCOPY; TUMOR VOLUME; TUMOR XENOGRAFT; TYLOPHORA; TYLOPHORA ATROFOLLICULATA; TYLOPHORA OVATA;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CIRCULAR DICHROISM; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; INDOLIZIDINES; INTERCALATING AGENTS; MALE; MICE; NUCLEIC ACID CONFORMATION; PHENANTHROLINES; SPECTROMETRY, FLUORESCENCE; TYLOPHORA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052328930     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000329506     Document Type: Article

References (34)

1. Gellert E: The indolizidine alkaloids. J Nat Prod 1982; 45: 50-73. (Pubitemid 12102893)
2. Chemler SR: Phenanthroindolizidines and phenanthroquinolizidines: promising alkaloids for anti-cancer therapy. Curr Bioact Compd 2009; 5: 2-19.
3. Rathnagiriswaran AN, Venkatachalam K: The chemical examination of Tylophora asthmatica and isolation of the alkaloids tylophorine and tylophorinine. Indian J Med Res 1935; 22: 433.
4. Grant P, Sánchez L, Jiménez A: Cryptopleurine resistance: genetic locus for a 40S ribosomal component in Saccharomyces cerevisiae . J Bacteriol 1974; 120: 1308-1314.
5. Rao KN, Bhattacharya RK, Venkatachalam SR: Thymidylate synthase activity in leukocytes from patients with chronic myelocytic leukemia and acute lymphocytic leukemia and its inhibition by phenanthroindolizidine alkaloids pergularinine and tylophorinidine. Cancer Lett 1998; 128: 183-188. (Pubitemid 28318734)
6. Rao KN, Venkatachalam SR: Inhibition of dihydrofolate reductase and cell growth activity by the phenanthroindolizidine alkaloids pergularinine and tylophorinidine: the in vitro cytotoxicity of these plant alkaloids and their potential as antimicrobial and anticancer agents. Toxicol In Vitro 2000; 14: 53-59. (Pubitemid 30122814)
7. Shiah HS, Gao W, Baker DC, Cheng YC: Inhibition of cell growth and nuclear factorkappaB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503. Mol Cancer Ther 2006; 5: 2484-2493. (Pubitemid 44650912)
8. Huang MT, Grollman AP: Mode of action of tylocrebrine: effects on protein and nucleic acid synthesis. Mol Pharmacol 1972; 8: 538-550.
9. You X, Pan M, Gao W, et al: Effects of a novel tylophorine analog on collagen-induced arthritis through inhibition of the innate immune response. Arthritis Rheum 2006; 54: 877-886.
10. Garbett NC, Ragazzon PA, Bhaires JB: Circular dichroism to determine binding mode and affinity of ligand-DNA interactions. Nat Protoc 2007; 2: 3166-3172.
11. Willis B, Arya DP: Recognition of B-DNA by neomycin-Hoechst 33258 conjugates. Biochemistry 2006; 45: 10217-10232. (Pubitemid 44384797)
12. Hwangbo HJ, Yun BH, Cha JS, Kwon DY, Kim SK: Enantioselective binding of S-and R-ofloxacin to various synthetic polynucleotides. Eur J Pharm Sci 2003; 18: 197-203. (Pubitemid 36184759)
13. Xi Z, Zhang R, Yu Z, Ouyang D, Huang R: Selective interaction between tylophorine B and bulged DNA. Bioorg Med Chem Lett 2005; 15: 2673-2677. (Pubitemid 40615010)
14. Norden B, Kurucsev T: Analysing DNA complexes by circular and linear dichroism. J Mol Recognit 1994; 7: 141-156. (Pubitemid 2126078)
15. Ivanov VI, Minchenkova LE, Schyolkina AK, Poletayev AI: Different conformations of double-stranded nucleic acid in solution as revealed by circular dichroism. Biopolymers 1973; 12: 89-110.
16. Lyng R, Hard T, Norden B: Induced CD of DNA intercalators: electric dipole allowed transitions. Biopolymers 1987; 26: 1327-1345.
17. Olsthoorn CS, Bostelaar LJ, Derooij JF, Vanboom JH, Altona C: Circular dichroism study of stacking properties of oligodeoxyadenylates and polydeoxyadenylate. Eur J Biochem 1981; 115: 309-321.
18. Norden B, Tjerneld F: Structure of methylene blue-DNA complexes studied by linear and circular dichroism spectroscopy. Biopolymers 1982; 21: 1713-1734. (Pubitemid 13253070)
19. Liu Y, Kumar A, Boykin DW, Wilson WD: Sequence and length dependent thermodynamic differences in heterocyclic diamidine interactions at AT base pairs in the DNA minor groove. Biophys Chem 2007; 131: 1-14. (Pubitemid 350030990)
20. Bhadra K, Maiti M, Kumar GS: Molecular recognition of DNA by small molecules: AT base pair specific intercalative binding of cytotoxic plant alkaloid palmatine. Biochim Biophys Acta 2007; 1770: 1071-1080. (Pubitemid 46678609)
21. Vives M, Tauler R, Gargallo ER: Spectroscopic study of the interaction of actinomycin D with oligonucleotides carrying the central base sequences-XGCY-and-XGGCCY-using multivariate methods. Anal Bioanal Chem 2007; 387: 311-320. (Pubitemid 44956283)
22. Chen H, Liu X, Patel DJ: DNA bending and unwinding associated with actinomycin D antibiotics bound to partially overlapping sites on DNA. J Mol Biol 1996; 258: 457-479. (Pubitemid 26145894)
23. Yang XL, Wang AH: Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther 1999; 83: 181-215. (Pubitemid 29430122)
24. Pilch DS, Waring MJ, Sun JS, et al: Cha racterization of a triple helix-specific li-gand: BePI (3-methoxy-7H-8-methyl-11-[(3-amino)propylamino]- benzo[e]pyrido[4,3-b] indole) intercalates into both double-helical and triple-helical DNA. J Mol Biol 1993; 232: 926-946. (Pubitemid 23256983)
25. Palchaudhuri R, Hergenrother PJ: DNA as a target for anti cancer compounds: methods to determine the mode of binding and the mechanism of action. Curr Opin Biotechnol 2007; 18: 497-503.
26. Glinka EM, Andryushchenko AS, Sapozhnikov AM, Zatsepina OV: Construction of the plasmid for expression of ETA-EGFP fusion protein under control of the cytomegalovirus promoter and its effects in HeLa cells. Plasmid 2009; 62: 119-127.
27. Tan S, Wang C, Lu C, et al: Quercetin is able to demethylate the p16INK4a gene promoter. Chemotherapy 2009; 55: 6-10.
28. Harley CB, Reynolds RP: Analysis of E. coli promoter sequences. Nucleic Acids Res 1987; 15: 2343-2361.
29. Smale ST, Kadonaga JT: The RNA polymerase II core promoter. Annu Rev Biochem 2003; 72: 449-479. (Pubitemid 36930452)
30. Takeda S, Nakai T, Ikeda F, Hatano K: Overproduction of a metallo-lactamase by a strong promoter causes high-level imipenem resistance in a clinical isolate of Pseudomonas aeruginosa . Chemotherapy 2008; 54: 181-187. (Pubitemid 351929268)
31. Burden DA, Osheroff N: Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1998; 1400: 139-154. (Pubitemid 28475100)
32. Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM: Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 2006; 66: 4863-4871.
33. Eskiocak U, Ieri OD, Kars M, Biçer A, Gunduz U: Effect of doxorubicin on telomerase activity and apoptotic gene expression in doxorubicin-resistant and-sensitive MCF-7 cells: an experimental study. Chemotherapy 2008; 54: 209-216. (Pubitemid 351929272)
34. Thongphasuk P, Stremmel W, Chamulitrat W: 2,3-dehydrosilybin is a better DNA topoisomerase I inhibitor than its parental silybin. Chemotherapy 2009; 55: 42-48.